$1.19
+0.02
(+1.71%)▲
0.0%
Downside
Day's Volatility :3.25%
Upside
3.25%
18.74%
Downside
52 Weeks Volatility :70.34%
Upside
63.5%
Period | Apyx Medical Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.42% | -2.1% | 0.0% |
6 Months | -15.6% | 4.9% | 0.0% |
1 Year | -54.58% | 16.0% | 0.0% |
3 Years | -92.06% | 9.2% | -26.4% |
Market Capitalization | 40.5M |
Book Value | $0.43 |
Earnings Per Share (EPS) | -0.82 |
Wall Street Target Price | 3.5 |
Profit Margin | -57.86% |
Operating Margin TTM | -45.66% |
Return On Assets TTM | -21.83% |
Return On Equity TTM | -110.25% |
Revenue TTM | 49.0M |
Revenue Per Share TTM | 1.42 |
Quarterly Revenue Growth YOY | -10.5% |
Gross Profit TTM | 29.1M |
EBITDA | -21.7M |
Diluted Eps TTM | -0.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.71 |
EPS Estimate Next Year | -0.67 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.19 |
What analysts predicted
Upside of 194.12%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 16.7M | ↓ 57.09% |
Net Income | 64.0M | ↓ 1364.5% |
Net Profit Margin | 383.61% | ↑ 396.63% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 28.2M | ↑ 68.73% |
Net Income | -19.7M | ↓ 130.7% |
Net Profit Margin | -69.79% | ↓ 453.4% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↓ 1.57% |
Net Income | -11.9M | ↓ 39.41% |
Net Profit Margin | -42.96% | ↑ 26.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 48.5M | ↑ 75.08% |
Net Income | -15.2M | ↑ 27.67% |
Net Profit Margin | -31.33% | ↑ 11.63% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 44.5M | ↓ 8.26% |
Net Income | -23.3M | ↑ 53.14% |
Net Profit Margin | -52.3% | ↓ 20.97% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 52.3M | ↑ 17.61% |
Net Income | -18.7M | ↓ 19.61% |
Net Profit Margin | -35.75% | ↑ 16.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 3.72% |
Net Income | -3.5M | ↓ 41.76% |
Net Profit Margin | -29.09% | ↑ 19.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.6M | ↑ 11.75% |
Net Income | -994.0K | ↓ 71.86% |
Net Profit Margin | -7.33% | ↑ 21.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.0M | ↑ 17.72% |
Net Income | -4.6M | ↑ 365.69% |
Net Profit Margin | -28.98% | ↓ 21.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.7M | ↓ 8.21% |
Net Income | -9.6M | ↑ 107.54% |
Net Profit Margin | -65.52% | ↓ 36.54% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 14.5M | ↓ 0.84% |
Net Income | -7.6M | ↓ 21.14% |
Net Profit Margin | -52.11% | ↑ 13.41% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 16.44% |
Net Income | -6.6M | ↓ 13.46% |
Net Profit Margin | -53.96% | ↓ 1.85% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 95.6M | ↑ 208.54% |
Total Liabilities | 7.8M | ↓ 12.44% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 84.7M | ↓ 11.44% |
Total Liabilities | 13.4M | ↑ 71.09% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 74.1M | ↓ 12.48% |
Total Liabilities | 10.3M | ↓ 23.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 68.7M | ↓ 7.27% |
Total Liabilities | 14.7M | ↑ 43.5% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 51.8M | ↓ 24.66% |
Total Liabilities | 14.0M | ↓ 4.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 79.2M | ↑ 53.05% |
Total Liabilities | 52.3M | ↑ 274.18% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 56.8M | ↑ 9.67% |
Total Liabilities | 20.6M | ↑ 47.12% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.4M | ↑ 9.94% |
Total Liabilities | 25.7M | ↑ 24.92% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.4M | ↓ 4.78% |
Total Liabilities | 25.9M | ↑ 0.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 79.2M | ↑ 33.3% |
Total Liabilities | 52.3M | ↑ 102.31% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 70.7M | ↓ 10.76% |
Total Liabilities | 50.3M | ↓ 3.95% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 65.4M | ↓ 7.52% |
Total Liabilities | 50.5M | ↑ 0.44% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.0M | ↑ 467.25% |
Investing Cash Flow | 29.3M | ↓ 4795.67% |
Financing Cash Flow | -2.5M | ↑ 1292.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.5M | ↓ 12.07% |
Investing Cash Flow | 60.5M | ↑ 106.62% |
Financing Cash Flow | 147.0K | ↓ 105.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↓ 13.04% |
Investing Cash Flow | -581.0K | ↓ 100.96% |
Financing Cash Flow | -73.0K | ↓ 149.66% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.4M | ↓ 34.96% |
Investing Cash Flow | -723.0K | ↑ 24.44% |
Financing Cash Flow | 24.0K | ↓ 132.88% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.3M | ↑ 94.09% |
Investing Cash Flow | -1.0M | ↑ 39.7% |
Financing Cash Flow | 217.0K | ↑ 804.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 58.48% |
Investing Cash Flow | -110.0K | ↓ 22.54% |
Financing Cash Flow | 8.1M | ↓ 81220.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 157.95% |
Investing Cash Flow | 7.1M | ↓ 6564.55% |
Financing Cash Flow | 46.0K | ↓ 99.43% |
Sell
Neutral
Buy
Apyx Medical Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Apyx Medical Corp | -2.46% | -15.6% | -54.58% | -92.06% | -82.45% |
Stryker Corporation | 4.42% | 11.78% | 32.92% | 35.05% | 78.95% |
Boston Scientific Corp. | -0.24% | 14.78% | 59.19% | 94.87% | 104.05% |
Edwards Lifesciences Corp. | 3.32% | -20.77% | 0.7% | -42.4% | -13.89% |
Abbott Laboratories | 5.68% | 11.99% | 23.75% | -7.85% | 44.25% |
Medtronic Plc | 2.62% | 10.26% | 24.13% | -25.67% | -15.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Apyx Medical Corp | NA | NA | NA | -0.71 | -1.1 | -0.22 | NA | 0.43 |
Stryker Corporation | 38.19 | 38.19 | 2.49 | 12.05 | 0.19 | 0.07 | 0.01 | 52.87 |
Boston Scientific Corp. | 69.44 | 69.44 | 1.53 | 2.46 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 28.62 | 28.62 | 6.15 | 2.53 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 36.05 | 36.05 | 2.2 | 4.67 | 0.14 | 0.06 | 0.02 | 22.6 |
Medtronic Plc | 30.05 | 30.05 | 1.65 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Apyx Medical Corp | Buy | $40.5M | -82.45% | NA | -57.86% |
Stryker Corporation | Buy | $138.5B | 78.95% | 38.19 | 16.34% |
Boston Scientific Corp. | Buy | $123.7B | 104.05% | 69.44 | 11.26% |
Edwards Lifesciences Corp. | Buy | $40.7B | -13.89% | 28.62 | 65.86% |
Abbott Laboratories | Buy | $205.7B | 44.25% | 36.05 | 13.99% |
Medtronic Plc | Buy | $116.1B | -15.94% | 30.05 | 12.06% |
Insights on Apyx Medical Corp
Revenue is down for the last 4 quarters, 15.97M → 12.14M (in $), with an average decrease of 8.5% per quarter
Netprofit is up for the last 3 quarters, -9.60M → -6.55M (in $), with an average increase of 21.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 59.2% return, outperforming this stock by 113.8%
In the last 3 years, Boston Scientific Corp. has given 94.9% return, outperforming this stock by 187.0%
Archon Capital Management LLC
Royce & Associates, LP
Vanguard Group Inc
Horizon Asset Management Inc/ny
Taylor Frigon Capital Management LLC
Silverberg Bernstein Capital Management LLC
apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed
Organization | Apyx Medical Corp |
Employees | 252 |
CEO | Mr. Charles D. Goodwin II |
Industry | Health Technology |
Victoryshares International
$1.19
+1.71%
Clearbridge Focus Value Esg Etf
$1.19
+1.71%
Cabana Target Drawdwn 10 Etf
$1.19
+1.71%
Spdr Nyse Technology Etf
$1.19
+1.71%
Global Ship Lease Inc-cl A
$1.19
+1.71%
Standard Motor Products Inc
$1.19
+1.71%
Cp High Yield Trend Etf
$1.19
+1.71%
Gain Therapeutics Inc
$1.19
+1.71%
Olaplex Holdings, Inc.
$1.19
+1.71%